Bristol-Myers-AbbVie Drug Improves Remission in Blood Cancer

Updated on

An immune-based cancer therapy being developed by Bristol-Myers Squibb Co. and AbbVie Inc. improved remission rates in patients with a form of blood cancer by about five months, on average, compared with the current standard treatment in late-stage trials, potentially paving the way for U.S. Food and Drug Administration approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.